AMTI News and Press, Applied Molecular Transport Inc. From 12/22/22

AMT-101, an oral candidate for ulcerative colitis from Applied Molecular Transport ( NASDAQ: AMTI ), has failed in a phase 2 trial . Top-line data showed that that the clinical remission rate was higher in the placebo group than the treatment group. AMT-101 was given as a mono...

– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12 – AMT-101 was well-tolerated – Planned Phase 1b trial for the company’s second clinical asset, AMT-126, in UC patients –...

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for AMT-101 in patients with pouchitis, an indication with significant unmet me...

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation at the following investor conferences: Event: Guggenheim 4 th Annual Immunology a...

Applied Molecular Transport press release ( NASDAQ: AMTI ): Q3 GAAP EPS of -$0.65 in-line. Cash and cash equivalents. As of September 30, 2022, cash and cash equivalents were $76.0 million. Net loss for the third quarter of 2022 was $25.2 million, compared to $26.0 m...

Company held end of Phase 2 meeting with FDA to discuss advancing oral AMT-101 monotherapy to Phase 3 in chronic pouchitis, an orphan indication with no FDA-approved products Anticipate Phase 2 top-line readout for oral AMT-101 in UC monotherapy in late 2022 or early 2023, consi...

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the company has completed enrollment of the Phase 2 LOMBARD trial for AMT-101 in 105 patients with moderate-to-s...

Applied Molecular Transport press release ( NASDAQ: AMTI ): Q2 GAAP EPS of -$0.93. Cash, cash equivalents and investments. As of June 30, 2022, cash and cash equivalents were $95.8 million. For further details see: Applied Molecular Transport GAAP EPS of -$0.93 ...

Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Orphan indication with no FDA-approved products Company granted end of Phase 2 meeting with FDA to discuss advancing into Phase 3 development Announced top-line data for ...

Gainers: Inspira Technologies Oxy ( IINN ) +98% . Cano Health CANO +18% . Veru VERU +16% . Amylyx Pharmaceuticals ( AMLX ) +13% . Equillium ( EQ ) +12% . Losers: Applied Molecular Transport AMTI -26% . HTG Molecular D...